Dimerix Ltd., of Melbourne, Australia, appointed David Packham chief medical officer. He will be responsible for the identification and engagement of clinical trial sites in Australia and will help to define and identify patient populations, particularly with respect to the rare disease focal segmental glomerulosclerosis. Packham is the director of the Melbourne Renal Research Group, a specialist research facility for nephrology studies, and has extensive experience in the design and conduct of phase II and III clinical trials in nephrology. He has served as Asia Pacific lead investigator on a number of pivotal international studies in nephrology over the last 10 years.